Transit Scientific’s XO Cross Microcatheters Introduced for Use in Complex Peripheral Vascular Interventions

January 11, 2022—Transit Scientific announced the commercial introduction of its 12 new hydrophilic-coated XO Cross microcatheters, which are designed to facilitate guidewire support, guidewire exchange, and contrast media injection during complex peripheral vascular interventions.

In November 2021, the company announced FDA 510(k) clearance for the 2-F XO Cross 14 microcatheter, the 2.6-F XO Cross 18 microcatheter, and the 3.8-F XO Cross 35 support catheter for use with standard 0.014-, 0.018-, and 0.035-inch guidewires in 90-, 135-, 150-, and 175-cm working lengths.

XO Cross devices feature nontapered, metal-alloy, and polymer construction that provides high fatigue resistance against tough lesions found in late-stage peripheral artery disease and critical limb ischemia, stated the company.

Transit Scientific advised that Jihad Mustapha, MD, interventional cardiologist at Advanced Cardiac & Vascular Center in Grand Rapids, Michigan, performed procedures using 2-F XO Cross 14 microcatheters in 90- and 175-cm lengths.

“The 1:1 torque of the XO Cross 14 provided new levels of trackability during the procedures,” commented Dr. Mustapha in the company’s press release. “The XO Cross 14 performed well when treating anterior tibial artery to posterior tibial artery pedal loop chronic total occlusions (CTOs), showing uniquely impressive navigation throughout the pedals, saving time and elevating treatment capabilities.”

Dr. Mustapha added, “The XO Cross 14 enabled me to effectively cross four chronic CTOs in the pedal loop and then push up into the proximal posterior tibial to treat an additional CTO during a limb salvage procedure. I would not have been able to access this CTO without the XO Cross 14 catheter.”